Cereno Scientific receives approval for the start of a Phase II clinical trial in Russia
Cereno Scientific AB announces today, that the authorities in Russia have issued approval regarding the company's application to initiate a Phase II clinical trial with the drug candidate CS1. The company intends to start the study the first half of 2020 with the intention of demonstrating CS1's preventative effect against the formation of blood clots after orthopedic surgery.– It is with great pleasure that we can now confirm that the authorities in Russia have approved the start of our Phase II study in Russia, which we intend to initiate during the first half of 2020. The approval is a